Crossmark

A Response to: Letter to the Editor Regarding “Comparing Cardiovascular Outcomes and Costs of Perindopril-, Enalapril- or Losartan-Based Antihypertensive Regimens in South Africa: Real-World Medical Claims Database Analysis”

Crossref DOI link: https://doi.org/10.1007/s12325-024-03045-y

Published Online: 2024-11-19

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Snyman, Jacques R.

Gumedze, Freedom

Jones, Erika S. W.

Alaba, Olufunke A.

Tsabedze, Nqoba

Vira, Alykhan

Ntusi, Ntobeko A. B. https://orcid.org/0000-0003-2347-7883
License Information

Text and Data Mining valid from 2024-11-19

Version of Record valid from 2024-11-19
More Information

Article History

Received: 5 June 2024

Accepted: 18 October 2024

First Online: 19 November 2024

Declarations

:

: Jacques R. Snyman has received honoraria from Servier. Freedom Gumedze has received honoraria from Servier. Erika S. W. Jones has received sponsorship and honoraria from Servier and Pharmadynamics. Olufunke A. Alaba has received honoraria from Servier. Nqoba Tsabedze has received consultation fees from Novartis Pharmaceuticals, Novo Nordisk, Boston Scientific, Pfizer, Servier, Phillips, Takeda, AstraZeneca, Acino Health Care Group and Merck; and educational and travel grants from Medtronic, Biotronik, Boston Scientific and Vertice Health Care Group. Alykhan Vira is an employee of Quantium Health South Africa. Ntobeko A. B. Ntusi acknowledges support from the South African Medical Research Council, National Research Foundation and the Lily and Ernst Hausmann Trust; unrestricted educational grants from Siemens, General Electric, Philips and CVI42. Ntobeko Ntusi has changed his affiliation to the South African Medical Research Council.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below